knowledge -WSS

knowledge

author：explore 2025-09-30 17:17:18 - browse：32399

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA clears Verve to begin U.S. study of gene

entertainment

focus

leisure time

WSS

EpiPen alternative approval delay highlights citizen petition issue

Second xenotransplant done with gene

STAT Summit: Ending the crisis of Black deaths in the U.S.

Why a market frenzy over new weight loss drugs defies logic

CDC's new outbreak response network to include Northeastern

Cassava Sciences’ Alzheimer’s clinical trials should be halted

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: Ending the crisis of Black deaths in the U.S.

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Drug for rare kidney disease narrowly misses mark in clinical trial

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Experts study whether long Covid risk adds up with each reinfection

Wildfire smoke exposes gaps in outdoor worker protections

Drug for rare kidney disease narrowly misses mark in clinical trial

23andMe had bad news about my health. I wish a person had delivered it

STAT Readout: Friday, Oct. 20 biotech updates

hotspot

Biotech stock slump in 2023: awaiting the turnaround

Drug for rare kidney disease narrowly misses mark in clinical trial

Drug for rare kidney disease narrowly misses mark in clinical trial

Roivant's CEO is a star, but biotech's black hole persists

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

CZI to create biohub to build anti

entertainment

focus

leisure time

knowledge